BACKGROUND: The etiology of @entity1691 ( @entity1691 ) is not fully elucidated. Research continues in determining the mechanisms responsible for initiation of the disease process, its maintenance and development. OBJECTIVES: The aim of this study was to evaluate the expression of transcription factors STAT (signal transducer and activator of transcription) and NF-kB (nuclear factor kappa B) as well as @entity7803 ( @entity7803 ) in the peripheral blood leukocytes. We also analyzed the connection between the degree of activation of transcription factors and the disease activity. MATERIAL/METHODS: The study involved 46 @entity1 with @entity1691 and 19 healthy individuals who comprised the control group. The expression of NF-kB, @entity6897 , @entity4104 , @entity7116 , @entity11715 , @entity8850 , and @entity7803 in peripheral blood leukocytes was assessed. To determine the degree of activation of transcription factors STAT-s and NF-kB and @entity7803 kinase, the immunocytochemistry method was used. For location of the factors, the primary monoclonal anti-NF-kB, anti- @entity7803 and polyclonal anti-STAT-s antibodies were used (Chemicon International, USA, Abcam, Cambridge, UK), and the set of antibodies Novocastain Super ABC Kit (Novocastra, UK). RESULTS: Expression of @entity6897 , @entity4104 , @entity7116 , @entity11715 , @entity8850 , NF-kB and @entity7803 was statistically higher in the group of @entity1 with @entity1691 than in the control group. There was a positive correlation with ESR values and expression of @entity7116 . There was no correlation between STAT, NF-kB, and @entity7803 expression and ASDAS, BASDAI, and BASFI. Nine @entity1 were treated with @entity310 inhibitors. The expression of NF-kB and @entity8850 was higher in the group treated with @entity310 inhibitors, even though disease activity in these @entity1 was shown to be lower than in those not receiving such treatment (ASDAS = 1.34  0.51 vs. 3.52  0.90, BASDAI = 2.34  1.92 vs. 5.51  2.41). CONCLUSIONS: In the group of @entity1 with @entity1691 compared with the control group, higher expression of the transcription factors STAT and NF-kB as well as @entity7803 was observed. Due to its crucial roles in @entity32 and autoimmunity, @entity7116 may have promise as an effective therapeutic target for @entity1691 .

Activity of JAK/STAT and NF-kB in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity11715 :: ('6776', 'Gene') :: ['STAT5'] @entity8850 :: ('6778', 'Gene') :: ['STAT6'] @entity310 :: ('7124', 'Gene') :: ['TNF-a'] @entity4104 :: ('6774', 'Gene') :: ['STAT3'] @entity1691 :: ('MESH:D013167', 'Disease') :: ['axial spondyloarthritis', 'axSpA'] @entity6897 :: ('6772', 'Gene') :: ['STAT1'] @entity7803 :: ('3718', 'Gene') :: ['Janus kinase3', 'JAK3'] @entity7116 :: ('6775', 'Gene') :: ['STAT4']
@entity1691 :: (MESH:D013167,Disease) :: ['axial spondyloarthritis']
